Get to know our clinical trials

Trial of TNB314 in monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced malignant solid tumors.

THE PURPOSE OF THIS TRIAL IS TO TEST DIFFERENT DOSES OF THE TRIAL DRUG TO FIND THE ONE THAT IS SAFE AND WORKS FOR YOUR CANCER.

Imagen del Dr. Ignacio Melero Bermejo, especialista en Inmunología de la Clínica Universidad de Navarra.
Dr. Ignacio Melero Bermejo Curriculum
Codirector Immunology and Immunotherapy Department
Navarre headquarters
Cancer Center
Lung Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • FIRST HUMAN, OPEN-LABEL, DOSE-ESCALATING, EXTENDED COHORT TRIAL TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF TNB314 IN MONOTHERAPY AND IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED MALIGNANT SOLID TUMORS
  • Code EudraCT: 2023-506053-38-00
  • Protocol number: BNT314-01
  • Promoter: BioNTech SE

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION